NASDAQ:EVOK Evoke Pharma (EVOK) Stock Price, News & Analysis $7.08 +1.78 (+33.58%) (As of 10/28/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends About Evoke Pharma Stock (NASDAQ:EVOK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Evoke Pharma alerts:Sign Up Key Stats Today's Range$6.83▼$12.3250-Day Range$3.87▼$7.0852-Week Range$3.54▼$17.88Volume21.08 million shsAverage Volume126,475 shsMarket Capitalization$60.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Read More… Unveiled: NVIDIA’s "Secret Royalty" Program (Ad)Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?Click Here to learn how to get in now >>> Evoke Pharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks14th Percentile Overall ScoreEVOK MarketRank™: Evoke Pharma scored higher than 14% of companies evaluated by MarketBeat, and ranked 964th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Evoke Pharma.Read more about Evoke Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Evoke Pharma is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evoke Pharma is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Evoke Pharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.46% of the float of Evoke Pharma has been sold short.Short Interest Ratio / Days to CoverEvoke Pharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evoke Pharma has recently decreased by 72.31%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEvoke Pharma does not currently pay a dividend.Dividend GrowthEvoke Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.46% of the float of Evoke Pharma has been sold short.Short Interest Ratio / Days to CoverEvoke Pharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evoke Pharma has recently decreased by 72.31%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News Sentiment0.48 News SentimentEvoke Pharma has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Evoke Pharma this week, compared to 1 article on an average week.Search Interest2 people have searched for EVOK on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Evoke Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.10% of the stock of Evoke Pharma is held by insiders.Read more about Evoke Pharma's insider trading history. Receive EVOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address EVOK Stock News HeadlinesEvoke Pharma (NASDAQ:EVOK) Now Covered by StockNews.comOctober 29 at 1:41 AM | americanbankingnews.comEvoke Pharma Stock Is Soaring Monday: What's Going On?October 28 at 10:59 AM | benzinga.comWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…October 29, 2024 | Porter & Company (Ad)Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI®October 28 at 10:59 AM | finance.yahoo.comEvoke stock rockets 90% on study of Gimoti in GLP-1 usersOctober 28 at 10:59 AM | msn.comEvoke Pharma Shares Rise 70% on Gimoti Data in GLP-1 UsersOctober 28 at 10:59 AM | marketwatch.comEvoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific MeetingOctober 23, 2024 | globenewswire.comEvoke Pharma appoints Ben Smeal to board of directorsOctober 23, 2024 | markets.businessinsider.comSee More Headlines EVOK Stock Analysis - Frequently Asked Questions How have EVOK shares performed this year? Evoke Pharma's stock was trading at $12.6036 at the start of the year. Since then, EVOK shares have decreased by 43.8% and is now trading at $7.08. View the best growth stocks for 2024 here. How were Evoke Pharma's earnings last quarter? Evoke Pharma, Inc. (NASDAQ:EVOK) announced its quarterly earnings results on Tuesday, August, 13th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.72) by $0.21. The specialty pharmaceutical company had revenue of $2.55 million for the quarter. Evoke Pharma had a negative net margin of 86.74% and a negative trailing twelve-month return on equity of 964.25%. When did Evoke Pharma's stock split? Evoke Pharma shares reverse split before market open on Thursday, August 1st 2024. The 1-12 reverse split was announced on Thursday, August 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Evoke Pharma? Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Evoke Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evoke Pharma investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings8/13/2024Today10/28/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EVOK CUSIPN/A CIK1403708 Webwww.evokepharma.com Phone(858) 345-1494FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,790,000.00 Net Margins-86.74% Pretax Margin-86.74% Return on Equity-964.25% Return on Assets-66.09% Debt Debt-to-Equity RatioN/A Current Ratio1.28 Quick Ratio1.22 Sales & Book Value Annual Sales$7.53 million Price / Sales8.09 Cash FlowN/A Price / Cash FlowN/A Book Value($9.26) per share Price / Book-0.76Miscellaneous Outstanding Shares8,597,000Free Float769,000Market Cap$60.87 million OptionableNot Optionable Beta0.39 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:EVOK) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evoke Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.